Fig. 3.

Anti-CCR7 mAb complement-mediated activity is highly effective against CLL cells from patients refractory to both fludarabine and alemtuzumab (FAR). PBMC from patients 10 and 14 (Table 1) were incubated with anti-CCR7, anti-CD52 (alemtuzumab, Alem) or an isotype control (IC) at the indicated concentrations and then exposed to rabbit complement for 1.5 h. Cell lysis was determined in the different populations by staining CD19, CD3 and CD5 and analyzing 7-AAD (7-aminoactinomycin-D) incorporation by FCM. In all cases, the percentage of specific lysis was calculated according to the formula shown in “Materials and methods”. a Specific lysis of CLL cells from patient 10. b Specific lysis of CLL cells from patient 14. In both patients, results from one experiment are shown